A Phase 1, Open-label Trial to Evaluate the Effect of Food on the Pharmacokinetics of Emraclidine in Healthy Adult Participants
Latest Information Update: 28 Nov 2023
At a glance
- Drugs Emraclidine (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Cerevel Therapeutics
- 22 Nov 2023 Status changed from active, no longer recruiting to completed.
- 26 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2023 Status changed from not yet recruiting to recruiting.